Abstract
This review article describes the development of in vivo active antagonists for the glycine binding site of the NMethyl- D-Aspartate (NMDA) receptor. There were several difficulties in identifying a class of antagonists with in vivo efficacy and only a few compounds succeeded in emerging with activity in vivo. A series of tricyclic quinoxalinediones was highly potent glycine antagonists in vitro and the derivatives having a zwitterionic moiety including SM-18400 indeed showed in vivo activity. Similarly, tricyclic indole-2-carboxylic acids having a zwitterionic moiety such as SM- 31900 were also active in vivo. In fact, SM-18400 and SM-31900 exhibited efficacy in several animal stroke models using intravenous infusion protocols. The practical syntheses of SM-18400 and SM-31900 as well as the novel synthesis of moderately active glycine antagonists, tricyclic azakynurenic acids, were also developed.
Keywords: N-Methyl-D-Aspartate, NMDA-glycine antagonist, SM-18400, SM-31900, tricyclic quinoxalinedione, tricyclic indole-2-carboxylic acid
Current Topics in Medicinal Chemistry
Title: Tricyclic Quinoxalinediones, Aza-kynurenic Acids, and Indole-2- Carboxylic Acids as In Vivo Active NMDA-Glycine Antagonists
Volume: 6 Issue: 7
Author(s): Ryu Nagata, Seiji Katayama, Ken-ichi Ohtani, Hiroyasu Tanaka and Kozo Shimago
Affiliation:
Keywords: N-Methyl-D-Aspartate, NMDA-glycine antagonist, SM-18400, SM-31900, tricyclic quinoxalinedione, tricyclic indole-2-carboxylic acid
Abstract: This review article describes the development of in vivo active antagonists for the glycine binding site of the NMethyl- D-Aspartate (NMDA) receptor. There were several difficulties in identifying a class of antagonists with in vivo efficacy and only a few compounds succeeded in emerging with activity in vivo. A series of tricyclic quinoxalinediones was highly potent glycine antagonists in vitro and the derivatives having a zwitterionic moiety including SM-18400 indeed showed in vivo activity. Similarly, tricyclic indole-2-carboxylic acids having a zwitterionic moiety such as SM- 31900 were also active in vivo. In fact, SM-18400 and SM-31900 exhibited efficacy in several animal stroke models using intravenous infusion protocols. The practical syntheses of SM-18400 and SM-31900 as well as the novel synthesis of moderately active glycine antagonists, tricyclic azakynurenic acids, were also developed.
Export Options
About this article
Cite this article as:
Nagata Ryu, Katayama Seiji, Ohtani Ken-ichi, Tanaka Hiroyasu and Shimago Kozo, Tricyclic Quinoxalinediones, Aza-kynurenic Acids, and Indole-2- Carboxylic Acids as In Vivo Active NMDA-Glycine Antagonists, Current Topics in Medicinal Chemistry 2006; 6 (7) . https://dx.doi.org/10.2174/156802606776894500
DOI https://dx.doi.org/10.2174/156802606776894500 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Metabolism and Pharmacological Mechanisms of Active Ingredients in <i>Erigeron breviscapus</i>
Current Drug Metabolism MicroRNAs as Therapeutic Targets for Anticancer Drugs in Lung Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry A More Accurate Approach to Molecular Genetics Analysis in Vascular Disease
Cardiovascular & Hematological Disorders-Drug Targets Loneliness and Social Isolation: Determinants of Cardiovascular Outcomes
Current Cardiology Reviews Evaluation of Plasma Homocysteine Levels as a Prognostic Factor for the Occurrence of Perioperative Myocardial Infarction in Coronary Artery Bypass Grafting: A Pilot Study
Vascular Disease Prevention (Discontinued) Your Father and Grandfather’s Atrial Fibrillation: A Review of the Genetics of the Most Common Pathologic Cardiac Dysrhythmia
Current Genomics The Antagonists of Endothelin Receptors: Results and Perspectives
Current Pharmaceutical Analysis Potential Roles of Selenium and Selenoproteins in the Prevention of Alzheimer's Disease
Current Topics in Medicinal Chemistry Synthesis of Natural and/or Biologically Relevant Three-membered Heterocycles and Derivatives through Asymmetric Epoxidation, Aziridination, Azirination and Thiirination
Letters in Organic Chemistry Role of Poly(ADP-ribose) Polymerase (PARP1) in Viral Infection and its Implication in SARS-CoV-2 Pathogenesis
Current Drug Targets Patent Selections
Recent Patents on Cardiovascular Drug Discovery Patient Adherence to Novel Oral Anticoagulants (NOACs) for the Treatment of Atrial Fibrillation and Occurrence of Associated Bleeding Events: A Systematic Review and Meta-analysis
Current Vascular Pharmacology Cholesterol Absorption Blockade with Ezetimibe
Current Drug Targets - Cardiovascular & Hematological Disorders The Role of IRE1 Signaling in the Central Nervous System Diseases
Current Neuropharmacology Initiation of Dialysis: A Mini-Review of a Changing Paradigm
Cardiovascular & Hematological Disorders-Drug Targets Possible Use of Autologous Stem Cell Therapies for Alzheimers Disease
Current Alzheimer Research Pre-hospital Fibrinolysis in the Management of Patients with ST Elevation Acute Coronary Syndrome: Review of the Evidence, Implementation and Future Directions
Cardiovascular & Hematological Disorders-Drug Targets Osteopontin; as a Target Molecule for the Treatment of Inflammatory Diseases
Current Drug Targets Hypothetical Role of Growth Factors to Reduce Intervertebral Disc Degeneration Significantly through Trained Biological Transformations
Current Pharmaceutical Design Protein-Protein Interaction (PPI) Network: Recent Advances in Drug Discovery
Current Drug Metabolism